iRadimed Corp (46K.HM) Seasonal returns chart
The article provides a seasonal returns chart for iRadimed Corp (46K.HM), displaying the average monthly price return from 2020 to 2026. As of November 10, the stock was trading at 75.50 EUR, down 1.31%.
iRadimed Corp (46K.DU) Seasonal returns chart
The article provides a seasonal returns chart for iRadimed Corp (46K.DU), showing the average monthly price return from 2024 to 2026. The stock is currently trading at 76.00 EUR, down 0.65% as of 12:30:18 CET. This data is available on Yahoo Finance, which also offers various other financial tools and market information.
IRADIMED (IRMD) Earnings And Guidance Put Valuation Back In Focus
IRADIMED (IRMD) recently released its Q3 results, Q4 and full-year 2026 guidance, and reaffirmed its cash dividend, leading to a mixed market reaction. Despite a recent share price bounce, the stock is down 9.62% year-to-date, though long-term returns remain strong. Analysts see the stock as undervalued at $86.31 compared to a $118 fair value, largely due to the anticipated replacement cycle for its new 3870 MRI compatible IV pump, while a P/E ratio of 46x suggests a premium compared to peers and the industry.
How Strong Earnings At IRADIMED (IRMD) Has Changed Its Investment Story
IRADIMED (IRMD) reported strong third-quarter 2026 results, with increased sales and net income, alongside a regular quarterly dividend declaration. The company's updated full-year guidance for revenue and GAAP diluted EPS provides investors with clearer insights into its balance of growth investments, profitability, and cash returns. This performance strengthens IRADIMED's investment narrative, particularly concerning its MRI-focused product lines and the ongoing rollout of its 3870 pump.
IRADIMED (IRMD) Shares Moved, What Is Behind The Latest Attention?
IRADIMED (IRMD) shares have gained attention following the release of their third-quarter 2026 results, new guidance, and a reaffirmed dividend. While the stock has seen a recent 3.57% gain, its 30-day and year-to-date returns are down, contrasting with strong longer-term performance. The article explores different valuation perspectives, including an "undervalued" narrative based on a new MRI-compatible IV pump and a "P/E lens" view suggesting the stock is richly valued.
IRadimed 3Q 2026: Revenue $24.2M, EPS $0.51— 10-Q Summary
IRadimed Corp. reported strong third-quarter 2026 results, with revenue increasing 14% year-over-year to $24.2 million and net income rising 16.7% to $6.5 million. Diluted earnings per share reached $0.51, up from $0.43 in the prior-year quarter. The company also highlighted significant international revenue growth and the completion of its expanded manufacturing facility.
IRadimed Down Over 8%, on Pace for Largest Percent Decrease Since April 2022 -- Data Talk
IRadimed shares fell over 8%, putting the company on track for its largest percentage decrease since April 2022. This significant downturn suggests a notable shift in investor sentiment or market performance for the company.
Iradimed Reports Record Q3 Revenue of $24.2 Million, Raises Dividend
Iradimed (IRMD) reported record third-quarter 2026 revenue of $24.2 million, a 14% increase year-over-year, and diluted GAAP earnings per share of $0.51. The company also declared a quarterly dividend of $0.20 per share and updated its full-year 2026 revenue outlook to $91.6 million to $93.1 million. Business highlights included record quarterly bookings, a 45% increase in domestic pump-channel bookings, and continued adoption of its 3870 MR IV pump.
IRadimed Corporation (IRMD) Seasonal returns chart
The article provides a seasonal returns chart for IRadimed Corporation (IRMD), displaying the average monthly price return from 2016 to 2026. It includes current stock data, recent price movements, and links to various financial analysis tools and historical data for the company.
Iradimed stock hits 52-week low at 76.39 USD
Iradimed Corporation's stock has hit a 52-week low at $76.39, despite a 1-year total return of nearly 14%. InvestingPro analysis indicates the stock appears overvalued relative to its Fair Value, although the company remains profitable with a P/E ratio of 43. This dip occurs even after IRadimed reported record third-quarter revenue for 2026, exceeding analyst expectations, yet the company adjusted its full-year outlook downward.
Revenue rises 14%, but IRADIMED (IRMD) lowers its 2026 revenue forecast ceiling.
IRADIMED Corporation reported a 14% increase in third-quarter 2026 revenue to $24.2 million and a 17% increase in net income to $6.5 million. The company announced a regular quarterly cash dividend of $0.20 per share. While Q3 performance was strong, IRADIMED revised its full-year 2026 revenue guidance downwards to $91.6 million–$93.1 million from an earlier range of $91.0 million–$96.0 million.
iRadimed Q3 2026 Earnings Call Transcript
iRadimed (NASDAQ: IRMD) reported record Q3 2026 revenue of $24.2 million, a 14% year-over-year increase, primarily driven by strong sales and ramped production of its new 3870 MR IV pump and 3880 monitor. The company achieved GAAP earnings of $0.51 per share and non-GAAP earnings of $0.55 per share, with gross margins improving to 76%. Management expressed confidence in continued growth, expecting double-digit revenue increases for 2027 and a strong finish to 2026, with Q4 revenue projected between $25 million and $26.5 million.
Iradimed Corp. (IRMD) Reports In-Line Q3 EPS
Iradimed Corp. (IRMD) reported its Q3 earnings per share (EPS) of $0.55, which was in line with analyst estimates. The company also reported revenue of $24.2 million for the quarter, exceeding the consensus estimate of $23.47 million.
BlackRock reports voting power over 614,615 Iradimed (IRMD) shares alongside a passive stake.
BlackRock, Inc. has filed a SCHEDULE 13G/A, reporting a 4.96% passive stake in IRADIMED CORP (IRMD), totaling 634,738 shares as of September 30, 2026. The filing indicates BlackRock holds sole voting power over 614,615 shares and sole dispositive power over 634,738 shares. This disclosure highlights BlackRock's significant beneficial ownership in IRADIMED without seeking to change or influence control of the issuer.
IRADIMED CORPORATION (IRMD) Stock Price, News, Quote & History
This article provides a comprehensive overview of IRADIMED CORPORATION (IRMD) stock, including its current price, market performance, key financial metrics, and company profile. It details the company's products—MRI-compatible IV infusion pump and patient vital signs monitoring systems—and its market presence in the medical devices sector. The article also presents performance data, earnings trends, analyst insights, and valuation measures for IRMD.
Price to book forward of IRadimed Corp. – FWB:46K
This article provides the "Price to book forward" value for IRadimed Corp. (FWB:46K) on the Frankfurt Stock Exchange. It notes that the market is closed with no trades recorded. The information is sourced from ICE Data Services and FactSet Research Systems Inc., with SEC filings provided by Quartr.
IRadimed Corp. Estimates – LSX:A118V4
This article provides financial estimates and actuals for IRadimed Corp. (LSX:A118V4) available on TradingView. It allows users to explore reported financial data and analyst estimates across various statements, compare results with estimates, and visualize trends over time. The platform offers income statement, balance sheet, cash flow, and valuation metrics on both annual and quarterly bases.
Form 4 Iradimed Co For: 25 September By Investing.com
This article is a brief financial news item from Investing.com, stating that a Form 4 filing for Iradimed Co was released on September 25. The content largely consists of navigation links, popular searches, and market data, with the core information being the Form 4 announcement.
IRMD Form 4 Filings - iRadimed Corporation SEC Form 4
This article provides a comprehensive list of iRadimed Corporation (IRMD) Form 4 SEC filings over the last 12 months, detailing insider transactions such as stock unit conversions, sales by directors and the CEO, and equity award grants. The filings highlight sales conducted primarily through trusts linked to CEO Roger E. Susi under Rule 10b5-1 trading plans, as well as routine conversions of restricted stock units by other executives and directors. Each entry includes a Rhea-AI summary of the transaction, dates, prices, and resulting shareholdings.
IRADIMED Insiders Sell US$3.4m Of Stock, Possibly Signalling Caution
Over the last year, insiders at IRADIMED have sold shares worth US$3.4 million, which is significantly more than they bought. While this doesn't guarantee a share price decline, it suggests that some insiders may view the stock as less attractive now. Despite this, the company's shares are trading near their 52-week high, indicating strong recent performance.
IRadimed Director Joe Kiani Acquires 698 Shares Through RSU Vesting on September 23, 2026
IRadimed Director Joe Kiani acquired 698 shares of common stock on September 23, 2026, through the vesting of restricted stock units. This transaction, detailed in a Statement of Changes in Beneficial Ownership, is the first installment under the company's 2023 Equity Incentive Plan. Following the vesting, Kiani directly holds 698 shares of common stock and 1,397 remaining RSUs.
Form 4 Iradimed Co For: 25 September By Investing.com
This article from Investing.com UK reports on a Form 4 filing for Iradimed Co (IRMD) related to September 25, 2026. The brief article provides the company's stock performance for the day and the date of the filing. It also includes various market data and other news headlines.
698 stock units became shares for IRADIMED (NASDAQ: IRMD) director Joe E. Kiani.
IRADIMED CORP director Joe E. Kiani converted 698 restricted stock units into 698 common shares on September 23, 2026. Following this transaction, Kiani directly holds 1,397 restricted stock units and 698 common shares. These restricted stock units, granted under the company's 2023 Equity Incentive Plan, will vest in three equal annual installments starting September 23, 2026.
One-on-one investor meetings with Iradimed's CFO are set for New York
IRADIMED CORPORATION (NASDAQ: IRMD) announced that its CFO, Jack Glenn, will host one-on-one meetings with investors at the 5th Annual ROTH Healthcare Opportunities Conference in New York on September 29, 2026. The company specializes in developing MRI-compatible medical devices, including non-magnetic IV infusion pump systems and patient vital signs monitoring systems. This participation highlights Iradimed's ongoing engagement with the investment community.
Needham initiates IRadimed stock with Hold on valuation concerns By Investing.com
Needham initiated coverage on IRadimed Corp (NASDAQ:IRMD) with a Hold rating, citing valuation concerns despite a positive fundamental outlook. The medical device maker is considered overvalued based on its P/E ratio and EV/EBITDA multiple, even with plans for new product launches like a next-gen MRI compatible infusion pump and monitor. Although IRadimed shows strong fundamentals with a high gross profit margin and revenue growth, Needham prefers to wait for a better entry point due to the current stock valuation.
Needham initiates IRadimed stock with Hold on valuation concerns By Investing.com
Needham has initiated coverage of IRadimed Corp (NASDAQ:IRMD) with a Hold rating due to valuation concerns, despite acknowledging the medical device maker's strong fundamental outlook. The stock's current P/E ratio and EV/EBITDA multiples suggest it is overvalued according to InvestingPro analysis, with its growth potential largely priced in. IRadimed is poised for significant opportunities with new product launches, including a next-generation MRI compatible infusion pump and a new monitor, while maintaining robust financial health.
Needham initiates IRadimed stock with Hold on valuation concerns
Needham initiated coverage on IRadimed Corp (NASDAQ:IRMD) with a Hold rating due to valuation concerns, despite acknowledging the medical device maker's positive fundamental outlook and significant growth opportunities. The firm noted that IRadimed's current stock price already reflects its growth potential, prompting them to await a better entry point. The company recently surpassed Wall Street expectations in Q2 2026 financial results, with non-GAAP earnings of $0.46 per share and revenue of $20.47 million.
Iradimed director Monty Allen sells $122,621 in stock
Iradimed director Monty K. Allen sold 1,419 shares of IRADIMED CORP (NASDAQ: IRMD) common stock, totaling $122,621, with prices ranging from $86.35 to $86.44 per share. Following these transactions, Allen directly holds 19,581 shares. This sale comes as IRadimed recently reported better-than-expected Q2 2026 earnings, despite a product transition impacting margins.
Director at IRADIMED (IRMD) sells 1,419 shares
IRADIMED CORP director Monty K. Allen sold a total of 1,419 shares of common stock on September 3, 2026. The sales included 1,014 shares at a weighted average price of $86.44 and 405 shares at $86.35, not under a Rule 10b5-1 trading plan. The Form 4 filing details these transactions and shows Mr. Allen's holdings after the sale to be 19,581 shares.
Iradimed director Monty Allen sells $122,621 in stock By Investing.com
Iradimed director Monty Allen sold 1,419 shares of common stock totaling $122,621 on September 3, 2026. The sales were executed at prices ranging from $86.35 to $86.44 per share, leaving Mr. Allen with 19,581 shares. This transaction follows the company's Q2 2026 financial results where IRadimed surpassed Wall Street expectations with non-GAAP earnings of $0.46 per share and $20.47 million in revenue.
Iradimed director Monty Allen sells $122,621 in stock
Iradimed director Monty K. Allen sold 1,419 shares of common stock totaling $122,621 on September 3, 2026, with prices ranging from $86.35 to $86.44 per share. Following the transactions, Mr. Allen directly holds 19,581 shares. This sale comes as the company's stock trades down roughly 14% year-to-date and recently reported exceeding Wall Street expectations for Q2 2026 earnings.
IRADIMED (NASDAQ: IRMD) director flags 1,102 RSU shares for possible sale
IRADIMED director Monty K. Allen has filed a Rule 144 notice, indicating the potential sale of IRMD common stock derived from Restricted Stock Unit (RSU) vesting related to his board service in 2024 and 2025. The filing specifies 317 RSU-related shares from 2024 vesting and 1,102 shares from 2025 vesting. This notice allows for future sales but does not guarantee that the shares will be sold.
Price to book forward of IRadimed Corp. – TRADEGATE:46K
This article presents financial information for IRadimed Corp. (TRADEGATE:46K), specifically focusing on its price-to-book forward ratio. The content is primarily a data point display from TradingView, indicating that the market is closed and no trades have occurred for this specific metric.
Rice Hall James & Associates LLC Invests $2.91 Million in iRadimed Corporation $IRMD
Rice Hall James & Associates LLC has acquired a new stake in iRadimed Corporation (NASDAQ:IRMD), purchasing 30,444 shares valued at approximately $2.91 million. This investment comes as iRadimed reports strong quarterly earnings, beating analyst expectations, and maintains a "Moderate Buy" consensus rating from Wall Street analysts, despite some recent downgrades. The company also declared a quarterly dividend of $0.20 per share.
iRadimed (NASDAQ:IRMD) Shares Cross Below 200 Day Moving Average - Time to Sell?
iRadimed (NASDAQ:IRMD) shares recently fell below their 200-day moving average, trading at $88.02 against an average of $94.77. Despite this, the company maintains a "Moderate Buy" consensus rating with a $120 target price and exceeded recent earnings and revenue estimates. iRadimed also declared a quarterly dividend of $0.20, representing an annualized yield of 0.9%.
IRMD Financials: Revenue Breakdown, Margins & Competitor Comparison
This article provides a financial overview of IRADIMED CORPORATION (IRMD), detailing its revenue breakdown, profitability margins, and a comparison with competitors. The company's main revenue source is MRI Compatible Patient Vital Signs Monitoring Systems, and it boasts strong gross, operating, and net margins, alongside a solid Return on Equity. A competitive analysis against DRTS and BVS highlights IRMD's strong market position and efficiency.
IRadimed (IRMD) Q2 2026 Earnings Call Transcript
IRadimed reported its Q2 2026 financial results, highlighting successful initial production of its new 3870 MR IV pump system and strong customer acceptance, with bookings more than double units shipped. Despite temporary gross margin compression due to manufacturing ramp-up inefficiencies, the company reaffirmed its full-year 2026 guidance, expecting improved efficiencies and continued growth in the latter half of the year, driven by the replacement of older pump systems and strong monitor sales.
iRadimed (NASDAQ:IRMD) Cut to "Hold" at Wall Street Zen
iRadimed (NASDAQ:IRMD) has been downgraded to a "Hold" rating by Wall Street Zen and Weiss Ratings, despite analysts maintaining a "Moderate Buy" consensus with an average price target of $120. The company recently surpassed quarterly earnings and revenue expectations. CEO Roger E. Susi sold 5,000 shares, and other insiders have sold shares totaling approximately $1.52 million in the last quarter, though institutional investors own a significant portion of the company.
IRadimed (IRMD) Q2 2026 Earnings Call Transcript
IRadimed reported its Q2 2026 financial results, achieving manufacturing targets for its new 3870 MR IV pump system and seeing strong customer acceptance for the four-channel quad pump. Despite a temporary decline in gross margins due to production ramp-up inefficiencies, the company reaffirmed its full-year 2026 guidance, expecting improved efficiencies and record gross margins by Q4. The company highlighted significant replacement opportunities for older pump systems and strong demand for its patient monitors, while also declaring a quarterly cash dividend.
IRADIMED (IRMD) Stock Drops As 3870 Ramp Cuts Gross Margin
IRADIMED (IRMD) stock dropped 4.6% despite posting Q2 revenue of US$20.5m and non-GAAP EPS of US$0.46. The company experienced a deliberate hit to its gross margin, which compressed from 78% to 74%, as the new 3870 MR intravenous pump moved into a higher volume production phase. While bookings outpaced shipments and full-year guidance was reaffirmed, bears remain concerned about margin risk due to the company's concentrated product set and the 3870 ramp.
IRADIMED CORPORATION to Hold Second Quarter 2026 Financial Results Conference Call on July 31, 2026
IRADIMED CORPORATION announced it will hold a conference call on July 31, 2026, to discuss its financial results for the second quarter of 2026. This press release provides informational purposes only regarding the upcoming financial disclosure. The company's stock symbol is IRMD.
IRadimed (NASDAQ:IRMD) Medical Devices Update Gains Market Attention Today
IRadimed (NASDAQ:IRMD) has gained market attention after its latest quarterly update highlighted its MRI-compatible monitoring technologies and infusion systems. The company specializes in medical devices designed for safe use in magnetic resonance imaging environments, addressing a critical need for patient monitoring and hospital safety. Its focus on product quality, regulatory compliance, and technological innovation within this niche market continues to drive demand as healthcare facilities modernize diagnostic capabilities.
IRADIMED CORP Q2 2026: Revenue $20.47M, EPS $0.41— 10-Q Summary
IRADIMED CORP reported its second-quarter 2026 results, showing flat revenue year-over-year at $20.47M, while net income and diluted EPS decreased due to margin pressure from new-product production. Revenue growth was driven by device launches and disposables, with a notable shift in geographic mix as international sales significantly increased. The company's gross margin was impacted by initial production inefficiencies, but cash from operations improved after a facility expansion.
IRadimed: Q2 Earnings Snapshot
This article provides a Q2 earnings snapshot for IRadimed. The content is concise and directly presents the company's performance for the quarter.
IRADIMED: More Than 70% of New Pump Orders Were Four-Pump Setups
IRADIMED (NASDAQ: IRMD) announced its Q2 2026 financial results, reporting $20.5 million in revenue, up 0.5% year-over-year, with GAAP diluted EPS of $0.41 and non-GAAP diluted EPS of $0.46. The company reaffirmed its full-year 2026 guidance, expecting $91.0–$96.0 million in revenue and GAAP EPS of $1.90–$2.05, and declared a quarterly cash dividend of $0.20 per share. A key highlight was the strong adoption of its new 3870 MR IV pump, with over 70% of new orders being for the four-pump "quad stack" configuration, indicating a significant product and customer mix transition.
Iradimed reports Q2 revenue $20.5M, EPS $0.41; raises dividend to $0.20 and reaffirms 2026 guidance
Iradimed (IRMD) reported Q2 revenue of $20.5 million and diluted EPS of $0.41, alongside declaring a $0.20 quarterly dividend. The company reaffirmed its Q3 and full-year 2026 revenue and GAAP EPS guidance, anticipating revenue between $91.0M–$96.0M and GAAP EPS of $1.90–$2.05 for the full year. Iradimed also launched production of its next-generation 3870 MR IV pump, expecting revenue and efficiency gains in the second half of 2026.
IRadimed: Q2 Earnings Snapshot
IRadimed Corp. (IRMD) reported a second-quarter profit of $5.2 million, or 41 cents per share, with adjusted earnings of 46 cents per share. The company generated $20.5 million in revenue for the period. Looking ahead, IRadimed forecasts third-quarter earnings between 54 and 59 cents per share on revenue of $23 million to $24.5 million, and full-year earnings of $2.09 to $2.24 per share with revenue between $91 million and $96 million.
Renaissance Technologies LLC Sells 15,700 Shares of iRadimed Corporation $IRMD
Renaissance Technologies LLC reduced its stake in iRadimed Corporation by 3.4% during the first quarter, selling 15,700 shares but still retaining 440,712 shares valued at approximately $42.4 million. Despite this sale, institutional investors collectively own 92.34% of the company, and analysts maintain a "Buy" rating with an average price target of $120. iRadimed also exceeded first-quarter earnings and revenue expectations and announced a quarterly dividend.
Iradimed earnings on deck as growth momentum faces Q2 test
Iradimed (IRMD) is set to report its second-quarter earnings, with analysts expecting $0.44 earnings per share on $20.35 million in revenue, a sequential decline from Q1. Investors will focus on the performance of its new MRI-compatible IV infusion pump, margin sustainability, and management's reaffirmation of full-year guidance. Despite anticipated Q2 softness, Wall Street maintains a "Strong Buy" rating with a target price suggesting 25% upside.
Record Results, New MRI Pump And Dividend Hike Might Change The Case For Investing In IRADIMED (IRMD)
IRADIMED (IRMD) recently reported record 2025 results, strong Q1 2026, and FDA clearance for its upgraded MRidium 3870 MRI IV infusion pump, alongside an increased quarterly dividend. These developments, particularly the new pump expected to drive replacement demand, are highlighted as potentially reshaping the investment narrative for the company. The article suggests that while the new pump presents a significant catalyst, investors should also consider the concentration risk around a single product family.